tldrdailynews.com logo

Biotech startup charts a GLP-1-free path to obesity treatment

1 min read
Source: STAT
Biotech startup charts a GLP-1-free path to obesity treatment
Photo: STAT
TL;DR

Mwyngil Therapeutics is a new biotech startup pursuing obesity treatment without GLP-1 targets, led by CEO Luba Greenwood, aiming to explore alternative mechanisms beyond the GLP-1–driven weight-loss wave.

Topics:healthbiotech#biotech#drug-development#glp-1#obesity#startups
Share this article
A new biotech startup tries to tackle obesity, but not in the way you might expect  STAT

Want the full story? Read the original reporting

Read on STAT